Molecular targets of glioma invasion

M. Nakada, S. Nakada, T. Demuth, Nhan Tran, D. B. Hoelzinger, M. E. Berens

Research output: Contribution to journalReview article

286 Citations (Scopus)

Abstract

Glioblastoma multiforme is the most common and lethal primary malignant brain tumor. Although considerable progress has been made in technical proficiencies of surgical and radiation treatment for brain tumor patients, the impact of these advances on clinical outcome has been disappointing, with median survival time not exceeding 15 months. Over the last 30 years, no significant increase in survival of patients suffering from this disease has been achieved. A fundamental source of the management challenge presented in glioma patients is the insidious propensity of tumor invasion into distant brain tissue. Invasive tumor cells escape surgical removal and geographically dodge lethal radiation exposure and chemotherapy. Recent improved understanding of biochemical and molecular determinants of glioma cell invasion provide valuable insight into the underlying biological features of the disease, as well as illuminating possible new therapeutic targets. These findings are moving forward to translational research and clinical trials as novel antiglioma therapies.

Original languageEnglish (US)
Pages (from-to)458-478
Number of pages21
JournalCellular and Molecular Life Sciences
Volume64
Issue number4
DOIs
StatePublished - Feb 2007
Externally publishedYes

Fingerprint

Glioma
Tumors
Brain Neoplasms
Brain
Tumor Escape
Translational Medical Research
Survival
Glioblastoma
Radiation
Chemotherapy
Therapeutics
Clinical Trials
Drug Therapy
Cells
Tissue
Neoplasms
Radiation Exposure

Keywords

  • Glioma
  • Invasion

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Cell Biology

Cite this

Nakada, M., Nakada, S., Demuth, T., Tran, N., Hoelzinger, D. B., & Berens, M. E. (2007). Molecular targets of glioma invasion. Cellular and Molecular Life Sciences, 64(4), 458-478. https://doi.org/10.1007/s00018-007-6342-5

Molecular targets of glioma invasion. / Nakada, M.; Nakada, S.; Demuth, T.; Tran, Nhan; Hoelzinger, D. B.; Berens, M. E.

In: Cellular and Molecular Life Sciences, Vol. 64, No. 4, 02.2007, p. 458-478.

Research output: Contribution to journalReview article

Nakada, M, Nakada, S, Demuth, T, Tran, N, Hoelzinger, DB & Berens, ME 2007, 'Molecular targets of glioma invasion', Cellular and Molecular Life Sciences, vol. 64, no. 4, pp. 458-478. https://doi.org/10.1007/s00018-007-6342-5
Nakada M, Nakada S, Demuth T, Tran N, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cellular and Molecular Life Sciences. 2007 Feb;64(4):458-478. https://doi.org/10.1007/s00018-007-6342-5
Nakada, M. ; Nakada, S. ; Demuth, T. ; Tran, Nhan ; Hoelzinger, D. B. ; Berens, M. E. / Molecular targets of glioma invasion. In: Cellular and Molecular Life Sciences. 2007 ; Vol. 64, No. 4. pp. 458-478.
@article{1dffddd72ca1471da8b77204c804c187,
title = "Molecular targets of glioma invasion",
abstract = "Glioblastoma multiforme is the most common and lethal primary malignant brain tumor. Although considerable progress has been made in technical proficiencies of surgical and radiation treatment for brain tumor patients, the impact of these advances on clinical outcome has been disappointing, with median survival time not exceeding 15 months. Over the last 30 years, no significant increase in survival of patients suffering from this disease has been achieved. A fundamental source of the management challenge presented in glioma patients is the insidious propensity of tumor invasion into distant brain tissue. Invasive tumor cells escape surgical removal and geographically dodge lethal radiation exposure and chemotherapy. Recent improved understanding of biochemical and molecular determinants of glioma cell invasion provide valuable insight into the underlying biological features of the disease, as well as illuminating possible new therapeutic targets. These findings are moving forward to translational research and clinical trials as novel antiglioma therapies.",
keywords = "Glioma, Invasion",
author = "M. Nakada and S. Nakada and T. Demuth and Nhan Tran and Hoelzinger, {D. B.} and Berens, {M. E.}",
year = "2007",
month = "2",
doi = "10.1007/s00018-007-6342-5",
language = "English (US)",
volume = "64",
pages = "458--478",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "4",

}

TY - JOUR

T1 - Molecular targets of glioma invasion

AU - Nakada, M.

AU - Nakada, S.

AU - Demuth, T.

AU - Tran, Nhan

AU - Hoelzinger, D. B.

AU - Berens, M. E.

PY - 2007/2

Y1 - 2007/2

N2 - Glioblastoma multiforme is the most common and lethal primary malignant brain tumor. Although considerable progress has been made in technical proficiencies of surgical and radiation treatment for brain tumor patients, the impact of these advances on clinical outcome has been disappointing, with median survival time not exceeding 15 months. Over the last 30 years, no significant increase in survival of patients suffering from this disease has been achieved. A fundamental source of the management challenge presented in glioma patients is the insidious propensity of tumor invasion into distant brain tissue. Invasive tumor cells escape surgical removal and geographically dodge lethal radiation exposure and chemotherapy. Recent improved understanding of biochemical and molecular determinants of glioma cell invasion provide valuable insight into the underlying biological features of the disease, as well as illuminating possible new therapeutic targets. These findings are moving forward to translational research and clinical trials as novel antiglioma therapies.

AB - Glioblastoma multiforme is the most common and lethal primary malignant brain tumor. Although considerable progress has been made in technical proficiencies of surgical and radiation treatment for brain tumor patients, the impact of these advances on clinical outcome has been disappointing, with median survival time not exceeding 15 months. Over the last 30 years, no significant increase in survival of patients suffering from this disease has been achieved. A fundamental source of the management challenge presented in glioma patients is the insidious propensity of tumor invasion into distant brain tissue. Invasive tumor cells escape surgical removal and geographically dodge lethal radiation exposure and chemotherapy. Recent improved understanding of biochemical and molecular determinants of glioma cell invasion provide valuable insight into the underlying biological features of the disease, as well as illuminating possible new therapeutic targets. These findings are moving forward to translational research and clinical trials as novel antiglioma therapies.

KW - Glioma

KW - Invasion

UR - http://www.scopus.com/inward/record.url?scp=33847336870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847336870&partnerID=8YFLogxK

U2 - 10.1007/s00018-007-6342-5

DO - 10.1007/s00018-007-6342-5

M3 - Review article

C2 - 17260089

AN - SCOPUS:33847336870

VL - 64

SP - 458

EP - 478

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 4

ER -